LITTLE KNOWN FACTS ABOUT INTERLEUKIN-2 THERAPY.

It is nicely understood that IL-2 is a pleiotropic cytokine positioned in the crossroads of T mobile activation and regulation. Therefore, it is actually critical to engineer an IL-2 molecule that is certainly biased in direction of effector cells bearing the intermediate affinity receptor, like naïve and memory CD8+ T cells and NK cells, versus T